Asthma inhaler plus ibuprofen fails to slow early Alzheimer's

A combination of two old medicines, an inhaled asthma drug and the painkiller ibuprofen, has failed to slow early Alzheimer's disease in a phase 3 trial of more than 600 people. The results, held back for almost six years after the trial ended, were published on 23 October 2026 in the Journal of Alzheimer's Disease.

The treatment, called ALZT-OP1, paired inhaled cromolyn with a low oral dose of ibuprofen. It was designed to calm inflammation in the brain. In the Cognite trial, it did no better than either drug alone on the main measure of memory and daily function after 72 weeks.

The authors point to a possible signal in people who do not carry APOE4, the main genetic risk factor for Alzheimer's, but that finding was not statistically significant. The paper was written by David Elmaleh and colleagues, including authors from PhenoNet, formerly of AZTherapies, the company that developed the treatment, and the Keck School of Medicine of the University of Southern California.

Why inflammation

For decades, Alzheimer's research has focused on amyloid, the sticky protein that builds up in plaques in the brain. Antibody drugs that clear amyloid, such as lecanemab and donanemab, are now approved in some countries and slow decline modestly in early disease.

Researchers have also long suspected that inflammation contributes to the disease. Microglia, the brain's immune cells, cluster around amyloid plaques. In some states they help clear debris; in others they release inflammatory substances that may damage nerve cells.

Population studies once suggested that people who took anti-inflammatory painkillers, such as ibuprofen, had a lower risk of Alzheimer's. Trials of these drugs in people with or at risk of dementia were largely disappointing.

The ALZT-OP1 idea

AZTherapies, a Boston company, proposed a different twist. Cromolyn, also called cromoglicate, is an old inhaled drug for asthma and allergies that stabilises mast cells, a type of immune cell. In laboratory work, the company reported that it affected amyloid and microglia.

According to a 2020 AZTherapies statement, ALZT-OP1 was a combination of two previously approved drugs, reformulated to be absorbed rapidly through the lungs and to cross the blood-brain barrier. The aim was to shift activated microglia from an inflammatory state to a protective one. The company planned to seek approval through a streamlined US route for reformulated approved drugs.

The published abstract describes the doses as inhaled cromolyn 17.1 mg and oral ibuprofen 10 mg. That ibuprofen dose is far lower than a standard painkiller tablet; we report it as stated in the paper.

The Cognite trial

Cognite (NCT02547818) was a phase 3, double-blind, placebo-controlled trial with four arms. It was run under a Special Protocol Assessment with the US Food and Drug Administration, an agreement on the trial design before it starts.

The main measure was change in the Clinical Dementia Rating Sum of Boxes (CDR-SB), which scores memory, orientation, judgement, community affairs, home life and personal care. Higher scores mean more impairment. Unusually, the main comparison was the combination against each drug alone, not against placebo. That design tests whether each part adds something.

What the trial found

In the modified intention-to-treat population of 594 people, the primary goal was not met.

Neither difference was close to statistical significance. The authors conclude that ALZT-OP1 did not show efficacy in an unselected early Alzheimer's population.

A signal by gene type

The researchers also looked at results according to APOE4 status. APOE4 is a common variant of a gene involved in fat transport and the strongest known genetic risk factor for late-onset Alzheimer's.

In people without APOE4, those on the combination declined less than those on placebo, by 0.96 points on CDR-SB (95% CI -2.00 to 0.08; p=0.069). The confidence interval crosses zero, so this is not statistically significant. Subgroup results like this are often chance findings, especially when the main result is negative.

The authors say the signal warrants a new trial in which patients are grouped by genotype from the start. That would be the proper way to test it.

Safety

According to the abstract, ALZT-OP1 was safe and well tolerated over 72 weeks. The abstract does not give detailed rates of side effects. Both medicines have long track records, cromolyn as an inhaled asthma drug and ibuprofen as a painkiller, though at different doses and in different formulations from those used here.

Why it took so long

According to a BioSpace announcement from AZTherapies in November 2020, the last patient finished the last visit that month, and the company expected to report topline results in the first quarter of 2021. No full public results followed at that time. The paper appeared almost six years later.

Delays in publishing negative results are a known problem in medicine. They can mislead doctors and patients about which treatments work, and they waste the contribution of the people who took part. Publishing even a negative result, as here, adds to the evidence.

How it fits with other Alzheimer's research

Cognite adds to a long list of negative trials of anti-inflammatory approaches in Alzheimer's. The approved amyloid antibodies remain the only treatments shown to slow decline in early disease, and their benefits are modest and come with risks, including brain swelling and bleeding.

Interest in neuroinflammation continues, with other drugs targeting microglia in development. Cognite suggests that repurposing old anti-inflammatory medicines is unlikely to be a simple answer.

Limits of the evidence

• The main comparison was against each drug alone, which made a positive result harder to achieve.
• The APOE4 finding is a subgroup analysis and not statistically significant.
• The results come years after the trial ended, and treatment standards and diagnostic tools have changed since.
• Several authors are linked to the company that developed the treatment.
• We could not access the full paper, only the published abstract.

What it means for patients

ALZT-OP1 is not approved and, on these results, is not an effective treatment for early Alzheimer's. People should not take ibuprofen or other anti-inflammatory painkillers to try to prevent or treat dementia, because these drugs carry risks of stomach bleeding, kidney problems and heart effects, especially in older people.

Anyone worried about memory should see their doctor. People with early Alzheimer's can ask their specialist about current treatment options and clinical trials.

This article explains published research and isn't medical advice. Talk to your own doctor or specialist team before changing any treatment.